Equillium, Inc.
NASDAQ:EQBiotechnology
+$0.05 today
- Market cap
- $92.20M
- Beta
- 1.76
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.20
Volume 0.60M
Average 0.60M
Returns on capital
Equillium, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-78.3%
avg -50.8%
ROIC
-83.3%
avg -53.6%
ROA
-70.2%
avg -42.9%
Analysis
ROA is currently the strongest return metric at -70.2% versus its period average of -42.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Bruce Steel | Co-Founder, Chief Executive Officer & Director | USD 1.23M | 60 | — | — |
Stephen Connelly | Chief Scientific Officer & President | USD 926.56K | 45 | 762.02K | 2.15% |
Christine Zedelmayer | Senior Vice President & Chief Operating Officer | USD 810.29K | 56 | 25.52K | 0.07% |
Lisette Acevedo | Vice President of Clinical Development | — | — | — | — |
Michael Moore | Vice President of Investor Relations & Corporate Communications | — | — | — | — |
Penny Tom | Senior Vice President of Finance & Principal Accounting Officer | — | — | 0 | <0.01% |
Snehal Naik | Chief Development Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
20
$2.76M
Net Transaction Value
−$2.76M
Net selling
Most Active
Zedelmayer Christine
16 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 5, 26Jun 5, 2026 | Connelly Stephen Direct | Sell | $91.1K$91,069.60 |
| Jun 5, 26Jun 5, 2026 | Zedelmayer Christine Direct | Sell | $42.7K$42,736.95 |
| Jun 4, 26Jun 4, 2026 | Connelly Stephen Direct | Sell | $632.8K$632,760.00 |
| May 28, 26May 28, 2026 | Tom Penny Direct | Sell | $191.8K$191,750.00 |
| May 28, 26May 28, 2026 | Zedelmayer Christine Direct | Sell | $150.1K$150,130.80 |
| May 28, 26May 28, 2026 | Zedelmayer Christine Direct | Sell | $542$542.00 |
| May 28, 26May 28, 2026 | Zedelmayer Christine Direct | Sell | $90K$90,019.84 |
| May 27, 26May 27, 2026 | Zedelmayer Christine Direct | Sell | $26.5K$26,516.70 |
| Mar 13, 26Mar 13, 2026 | Zedelmayer Christine Direct | Sell | $300.8K$300,816.09 |
| Mar 9, 26Mar 9, 2026 | Zedelmayer Christine Direct | Sell | $362.4K$362,438.00 |
1–10 of 20
Summary
Insiders reported 0 buys worth $0.00 and 20 sells worth $2.76M over the last 12 months. That adds up to net selling of $2.76M. Zedelmayer Christine was the most active insider with 16 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Equillium, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about EQ's management, answered from reported figures.
Who manages EQ?
Equillium, Inc. (EQ) lists 7 active executives. The top listed executive is Lisette Acevedo, Vice President of Clinical Development.
Are EQ insiders buying or selling?
Recent insider activity shows net buying of $2.87M.
Continue the stock analysis
Jump to another research area for this company.